The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter, MD, of Mount Sinai Medical Center, New York, NY, highlights how despite the emergence of new and very exiting data that support the use of 2, 3 and 4-drug combinations for multiple myeloma (MM), the key challenge is that that we still do not know what the right therapy is for the right person, and more so for the high-risk populations. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
